|
|||||
|
|
Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B |
|
| Authors: | K. Kavakli L. Smith K. Kuliczkowski J. Korth‐Bradley C. W. You J. Fuiman S. Zupančić‐Šalek F. Abdul Karim P. Rendo |
| Affiliation: | 1. Department of Pediatric Hematology, Ege University Children's Hospital, Izmir, Turkey;2. Pfizer Inc, Collegeville, PA, USA;3. University of Wroclaw, Wroclaw, Poland;4. Eulji University, Daejeon, Korea;5. University Hospital Centre Rebro, Zagreb, Croatia;6. National Blood Centre in Kuala Lumpur, Kuala Lumpur, Malaysia |
| Abstract: | |
| Keywords: | BeneFIX factor IX haemophilia B pharmacokinetics prevention safety |